Genomma Lab Ownership

Pink Sheets . USA . 
Stock . Genomma Lab Internacional
GNMLF Stock  USD 1.27  0.00  0.00%   
Genomma Lab Internacional has a total of 1 Billion outstanding shares. Genomma Lab secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as Genomma Lab in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Genomma Lab, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genomma Lab Internacional. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Genomma Pink Sheet Ownership Analysis

About 29.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.38. Some equities with similar Price to Book (P/B) outperform the market in the long run. Genomma Lab Internacional last dividend was issued on the 9th of November 2022. The entity had 2:1 split on the 3rd of August 2010. Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico. Genomma Lab operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2327 people.The quote for Genomma Lab Internacional is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Genomma Lab Internacional call the company at 52 55 5081 0000 or check out https://www.genommalab.com.

Currently Active Assets on Macroaxis

RSIRush Street Interactive
OKTAOkta Inc
BACBank of America
SSentinelOne
WDWalker Dunlop

Other Information on Investing in Genomma Pink Sheet

Genomma Lab financial ratios help investors to determine whether Genomma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genomma with respect to the benefits of owning Genomma Lab security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY